Overexpression of LncRNA SNHG1 Were Suitable for Oncolytic Adenoviruse H101 Therapy in Oral Squamous-Cell Carcinoma.

Abstract

BACKGROUND:

As the most prevalent type of head and neck cancer, oral squamous-cell carcinoma (OSCC) accounts for nearly 90% of all oral cancer cases. Despite great progress having been made in the diagnosis and treatment of OSCC recently, the survival rate of OSCC patients has not risen remarkably. Chemotherapy is commonly used for OSCC treatment; however, the emergence of chemoresistance limits its long-term curative effect. Therefore, identifying effective biomarkers and molecular mechanisms is essential to the development of therapeutic strategies for OSCC.

METHODS:

qRT-PCR assays were performed to detect SNHG1 expression in OSCC tissue and cells, and CCK8 assays and animal experiments used to examine cell proliferation. In addition, CCK8 assays were used to detect IC50 values of cisplatin, 5Fu, Dox, and oncolytic adenovirus H101.

RESULTS:

We found that SNHG1 was overexpressed in OSCC tissue and cells and was associated with OSCC progression. In addition, knockdown of SNHG1 suppressed cell proliferation in vitro and in vivo. Importantly, we found that oncolytic adenovirus H101 showed better antitumor effects in OSCC with high SNHG1 expression, and chemotherapy showed worse anti-tumor effects in OSCC with high SNHG1 expression.

CONCLUSION:

SNHG1 can act as a diagnostic biomarker for OSCC, and may be a biomarker for treatment options.

• Authors: Xin Wang, Song Yang, Xuechao Lv, Lina Wang, Chunmei Li
• Journal: OncoTargets and therapy (Onco Targets Ther) Vol. 13 Pg. 13033-13039 ( 2020) ISSN: 1178-6930 [Print] New Zealand
• PMID: 33376352 (Publication Type: Journal Article)
• Copyright: © 2020 Wang et al.